Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950455 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
A Phase 3 study, sponsored by Navidea Biopharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT01950455 is a Phase 3 study that was terminated before completion, run by Navidea Biopharmaceuticals. The registered enrollment target is 13 participants.
The verdict
NCT01950455, a Phase 3 study, was terminated before completion, sponsored by Navidea Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of \[123I\]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.
Interventions
- DRUG NAV5001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-11 |
| Est. Completion | 2018-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01950455
The ClinicalTrials.gov registry entry for NCT01950455 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NAV5001 is the first listed.
NCT01950455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01950455 about?
NCT01950455 is a clinical study titled "Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes". This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of \[123I\]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.
What is the current status of trial NCT01950455?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2013-11. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01950455?
The interventions under investigation include: NAV5001 (DRUG).
Who is sponsoring clinical trial NCT01950455?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.